GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Cyclically Adjusted Revenue per Share

Aceragen (Aceragen) Cyclically Adjusted Revenue per Share : $3.55 (As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aceragen's adjusted revenue per share for the three months ended in Mar. 2023 was $0.332. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.55 for the trailing ten years ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aceragen was 9.50% per year. The lowest was -26.80% per year. And the median was -0.55% per year.

As of today (2024-05-21), Aceragen's current stock price is $0.38. Aceragen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 was $3.55. Aceragen's Cyclically Adjusted PS Ratio of today is 0.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aceragen was 124.81. The lowest was 0.11. And the median was 33.85.


Aceragen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Aceragen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Cyclically Adjusted Revenue per Share Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.09 - - - 3.44

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 3.26 3.44 3.55

Competitive Comparison of Aceragen's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Aceragen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aceragen's Cyclically Adjusted PS Ratio falls into.



Aceragen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aceragen's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=0.332/127.3478*127.3478
=0.332

Current CPI (Mar. 2023) = 127.3478.

Aceragen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.104 98.518 0.134
201309 0.021 98.790 0.027
201312 0.008 98.326 0.010
201403 0.005 99.695 0.006
201406 0.062 100.560 0.079
201409 0.048 100.428 0.061
201412 0.003 99.070 0.004
201503 0.044 99.621 0.056
201506 0.006 100.684 0.008
201509 0.023 100.392 0.029
201512 0.213 99.792 0.272
201603 0.330 100.470 0.418
201606 0.337 101.688 0.422
201609 0.362 101.861 0.453
201612 14.202 101.863 17.755
201703 0.345 102.862 0.427
201706 0.170 103.349 0.209
201709 0.149 104.136 0.182
201712 0.130 104.011 0.159
201803 0.174 105.290 0.210
201806 0.102 106.317 0.122
201809 0.091 106.507 0.109
201812 0.062 105.998 0.074
201903 0.000 107.251 0.000
201906 0.865 108.070 1.019
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.016 125.227 0.016
202212 1.313 125.222 1.335
202303 0.332 127.348 0.332

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Aceragen  (NAS:ACGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aceragen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.38/3.55
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aceragen was 124.81. The lowest was 0.11. And the median was 33.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aceragen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aceragen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341